https://www.biopharmawatch.com/news/PHAR/fda-approves-pharming-joenja-treatment-apds-children BiopharmaWatch en 2026-09-11T18:00:00.000Z FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S. https://www.biopharmawatch.com/news/AHCO/adapthealth-participate-investor-conferences BiopharmaWatch en 2026-09-11T17:00:00.000Z AdaptHealth To Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/SNY/sanofi-voting-rights-shares-august-2026 BiopharmaWatch en 2026-09-11T16:30:00.000Z Sanofi: Information concerning the total number of voting rights and shares - August 2026 https://www.biopharmawatch.com/news/ARAY/accuray-raysearch-collaboration-online-adaptive-therapy BiopharmaWatch en 2026-09-11T15:28:00.000Z Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities https://www.biopharmawatch.com/news/LLY/lilly-acquires-ataibeckley-mental-health-therapies BiopharmaWatch en 2026-09-11T13:02:00.000Z Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-11T13:00:45.000Z Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/WAT/waters-corporation-jp-morgan-all-stars-conference BiopharmaWatch en 2026-09-11T13:00:00.000Z Waters Corporation to Present at the J.P. Morgan U.S. All Stars Conference https://www.biopharmawatch.com/news/PHGE/tessera-begins-trading-hlsq-demand-connected-security BiopharmaWatch en 2026-09-11T12:30:00.000Z Tessera Begins Trading Under HLSQ as Demand Grows for Connected Physical Security https://www.biopharmawatch.com/news/MBRX/moleculin-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-11T12:30:00.000Z Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-ltd-nasdaq-qntm-filling-key-gap-ms-treatment BiopharmaWatch en 2026-09-11T12:30:00.000Z Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-private-placement BiopharmaWatch en 2026-09-11T12:00:34.000Z Tempest Therapeutics Announces Up to $7.5 Million Private Placement https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-11-5-million-financing BiopharmaWatch en 2026-09-11T12:00:00.000Z Glucotrack Announces $11.5 Million Financing https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-effectiveness-1-80-reverse-stock-split BiopharmaWatch en 2026-09-11T12:00:00.000Z Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split https://www.biopharmawatch.com/news/IMMP/immutep-focused-development-strategy-efti BiopharmaWatch en 2026-09-11T12:00:00.000Z Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”) https://www.biopharmawatch.com/news/CMND/clearmind-enrolls-first-patients-aud-cmnd-100-trial BiopharmaWatch en 2026-09-11T12:00:00.000Z Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-spac-registration-filing BiopharmaWatch en 2026-09-11T12:00:00.000Z Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement https://www.biopharmawatch.com/news/GTBP/gt-biopharma-host-live-presentation-trike-platform BiopharmaWatch en 2026-09-11T12:00:00.000Z GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026 https://www.biopharmawatch.com/news/ELAN/elanco-third-quarter-2026-financial-results BiopharmaWatch en 2026-09-11T11:58:00.000Z Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement https://www.biopharmawatch.com/news/ELOX/eloxx-phase-2b-exact-study-exaluren BiopharmaWatch en 2026-09-11T11:30:00.000Z Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-11T11:01:00.000Z Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fireside-chat-hc-wainwright-conference BiopharmaWatch en 2026-09-11T11:00:00.000Z Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-hope-therapeutics-zeta-tms-robotic-system BiopharmaWatch en 2026-09-11T11:00:00.000Z NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System https://www.biopharmawatch.com/news/DARE/dare-bioscience-hc-wainwright-conference-presentation BiopharmaWatch en 2026-09-11T10:55:00.000Z Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand https://www.biopharmawatch.com/news/BLCO/bausch-lomb-ce-mark-approval-seelyra-laser BiopharmaWatch en 2026-09-11T10:11:00.000Z Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser https://www.biopharmawatch.com/news/YARW/yarrow-bioscience-pricing-public-offering BiopharmaWatch en 2026-09-11T01:11:00.000Z Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering https://www.biopharmawatch.com/news/NUTX/nutex-health-cybersecurity-update BiopharmaWatch en 2026-09-10T23:00:00.000Z NUTEX HEALTH PROVIDES UPDATE REGARDING CYBERSECURITY EVENT https://www.biopharmawatch.com/news/EW/edwards-lifesciences-tavr-coverage-decision BiopharmaWatch en 2026-09-10T21:49:00.000Z Edwards Lifesciences Comments on TAVR National Coverage Decision https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-files-shelf-prospectus BiopharmaWatch en 2026-09-10T21:00:00.000Z Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission https://www.biopharmawatch.com/news/JNJ/johnson-johnson-ce-marking-acuvue-oasys-max BiopharmaWatch en 2026-09-10T20:35:00.000Z Johnson & Johnson reçoit le marquage CE pour les lentilles de contact réutilisables ACUVUE OASYS MAX https://www.biopharmawatch.com/news/JNJ/jnj-ce-marking-acuvue-oasys-max-contact-lenses BiopharmaWatch en 2026-09-10T20:35:00.000Z Johnson & Johnson erhält CE-Kennzeichnung für wiederverwendbare Kontaktlinsen der Marke ACUVUE OASYS MAX https://www.biopharmawatch.com/news/JNJ/resumen-johnson-amp-johnson-obtiene-el-marcado-ce-para-las BiopharmaWatch en 2026-09-10T20:35:00.000Z Resumen: Johnson & Johnson obtiene el marcado CE para las lentillas reutilizables ACUVUE OASYS MAX https://www.biopharmawatch.com/news/JNJ/johnson-johnson-ce-mark-acuvue-oasys-max BiopharmaWatch en 2026-09-10T20:35:00.000Z Riassunto: Johnson & Johnson riceve il marchio CE per le lenti a contatto riutilizzabili ACUVUE OASYS MAX https://www.biopharmawatch.com/news/JNJ/ce-marking-johnson-johnson-acuvue-oasys-max BiopharmaWatch en 2026-09-10T20:35:00.000Z Samenvatting: Johnson & Johnson ontvangt CE-markering voor herbruikbare ACUVUE OASYS MAX-contactlenzen https://www.biopharmawatch.com/news/PSYC/psyched-wellness-secured-term-loan BiopharmaWatch en 2026-09-10T20:15:00.000Z Psyched Wellness Announces Secured Term Loan https://www.biopharmawatch.com/news/DXCM/dexcom-appoints-glenn-boehnlein-board-directors BiopharmaWatch en 2026-09-10T20:15:00.000Z Dexcom Appoints Glenn Boehnlein to Board of Directors https://www.biopharmawatch.com/news/A/agilent-participate-jp-morgan-all-stars-conference BiopharmaWatch en 2026-09-10T20:15:00.000Z Agilent to Participate in J.P. Morgan U.S. All Stars Conference https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-10T20:15:00.000Z Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-leadership-transition BiopharmaWatch en 2026-09-10T20:10:00.000Z TransCode Therapeutics Announces Leadership Transition https://www.biopharmawatch.com/news/SI/shoulder-innovations-fda-clearance-n22-humeral-head-launch BiopharmaWatch en 2026-09-10T20:05:00.000Z Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch https://www.biopharmawatch.com/news/TMDX/transmedics-appoints-fernando-araujo-cfo-2026-outlook BiopharmaWatch en 2026-09-10T20:05:00.000Z TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-appoints-vijay-iyengar-board BiopharmaWatch en 2026-09-10T20:05:00.000Z Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-lyl273-manufacturing-transfer-update BiopharmaWatch en 2026-09-10T20:05:00.000Z Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer https://www.biopharmawatch.com/news/SER/serina-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T20:05:00.000Z Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ELUT/elutia-presents-hc-wainwright-investment-conference-2026 BiopharmaWatch en 2026-09-10T20:05:00.000Z Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th https://www.biopharmawatch.com/news/YARW/yarrow-bioscience-public-offering BiopharmaWatch en 2026-09-10T20:03:00.000Z Yarrow Bioscience Announces Proposed Underwritten Public Offering https://www.biopharmawatch.com/news/SEPN/septerna-inc-announces-inducement-grant-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-09-10T20:00:00.000Z Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-virtual-investor-day-september-2026 BiopharmaWatch en 2026-09-10T20:00:00.000Z Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026 https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-analyst-event-rezilient3-trial BiopharmaWatch en 2026-09-10T17:00:00.000Z Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer https://www.biopharmawatch.com/news/CSBR/champions-oncology-reports-revenue-increase-q1-2027 BiopharmaWatch en 2026-09-10T16:00:00.000Z Champions Oncology Reports Revenue of $15.2 Million https://www.biopharmawatch.com/news/CDNL/hagens-berman-investigation-cardinal-infrastructure-group BiopharmaWatch en 2026-09-10T15:52:00.000Z HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Announces Investigation into Cardinal Infrastructure Group Inc. (NASDAQ: CDNL) Following Post-Offering Stock Plunge https://www.biopharmawatch.com/news/HONA/honeywell-aerospace-investigation-hona BiopharmaWatch en 2026-09-10T15:49:00.000Z HONA Alert: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Honeywell Aerospace Inc. (NASDAQ: HONA) Investors with Significant Losses to Contact Firm https://www.biopharmawatch.com/news/FCEL/fuelcell-fcel-stock-fall-fit-energy-disclosures BiopharmaWatch en 2026-09-10T15:47:00.000Z FuelCell (NASDAQ: FCEL) Scrutinized Over Fit Energy Disclosures Driving Stock Down 15% -- HBSS https://www.biopharmawatch.com/news/IMNN/imunon-nci-agreement-advance-imnn-001 BiopharmaWatch en 2026-09-10T13:30:00.000Z IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-fda-approval-lytenava BiopharmaWatch en 2026-09-10T13:10:00.000Z Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment https://www.biopharmawatch.com/news/AGL/agilon-health-family-practice-center-expansion BiopharmaWatch en 2026-09-10T13:00:00.000Z agilon health and Family Practice Center Expand Relationship Through Senior Health Connect ACO https://www.biopharmawatch.com/news/CODX/co-diagnostics-vector-smart-laboratory-installations BiopharmaWatch en 2026-09-10T13:00:00.000Z Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida https://www.biopharmawatch.com/news/TXG/lunit-collaboration-10x-genomics-ai-pathology-oncology BiopharmaWatch en 2026-09-10T13:00:00.000Z Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research https://www.biopharmawatch.com/news/NRSN/neurosense-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-10T13:00:00.000Z NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/POCI/precision-optics-receives-follow-on-production-orders BiopharmaWatch en 2026-09-10T13:00:00.000Z Precision Optics Announces Receipt of $1.3 Million Follow-On Production Orders from Large Defense Company https://www.biopharmawatch.com/news/OMDA/omada-health-investor-day-financial-targets BiopharmaWatch en 2026-09-10T13:00:00.000Z Omada Health to Present Updated Long-Term Financial Targets at Inaugural Investor Day https://www.biopharmawatch.com/news/LITS/lite-strategy-presents-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T13:00:00.000Z Lite Strategy to Present at the 28th Annual H.C. Wainwright Global Investment Conference in New York https://www.biopharmawatch.com/news/BNGO/bionano-laboratories-proposed-lcd-structural-variants BiopharmaWatch en 2026-09-10T13:00:00.000Z Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms https://www.biopharmawatch.com/news/FTRE/fortrea-september-investor-conferences-2026 BiopharmaWatch en 2026-09-10T12:58:00.000Z Fortrea to Participate in September Investor Conferences https://www.biopharmawatch.com/news/ABBV/abbvie-positive-phase-3-atogepant-results-menstrual-migraine BiopharmaWatch en 2026-09-10T12:55:00.000Z AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine https://www.biopharmawatch.com/news/OPTH/optimi-health-phase-2-trial-psilocybin-mdd BiopharmaWatch en 2026-09-10T12:45:00.000Z Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder https://www.biopharmawatch.com/news/ICU/seastar-medical-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T12:35:00.000Z SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/HYFT/mindwalk-participate-hc-wainwright-investment-conference BiopharmaWatch en 2026-09-10T12:34:00.000Z MindWalk to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-canaccord-genuity-well-summit BiopharmaWatch en 2026-09-10T12:32:00.000Z Niagen Bioscience to Present at Canaccord Genuity’s Well Summit https://www.biopharmawatch.com/news/DTR/diagnostear-positive-results-tearx-red-eye-study BiopharmaWatch en 2026-09-10T12:30:00.000Z DiagnosTear Announces Positive Final Results from Clinical Study Demonstrating Strong Diagnostic Performance of TeaRx(TM) Red Eye for Detecting Total Tear IgE as a Biomarker for Allergic conjunctivitis https://www.biopharmawatch.com/news/QTI/qt-imaging-participate-iaccess-alpha-conference BiopharmaWatch en 2026-09-10T12:30:00.000Z QT Imaging to Participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-netherton-now-video-aminah-story BiopharmaWatch en 2026-09-10T12:30:00.000Z Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU https://www.biopharmawatch.com/news/BCDA/biocardia-cardiamp-regulatory-progress-hc-wainwright-conference BiopharmaWatch en 2026-09-10T12:30:00.000Z BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-virtual-fireside-chat-september-2026 BiopharmaWatch en 2026-09-10T12:30:00.000Z Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-lucid-ms-phase-2-trial BiopharmaWatch en 2026-09-10T12:30:00.000Z Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market https://www.biopharmawatch.com/news/VNRX/volition-early-stage-cancer-detection-esmo-map BiopharmaWatch en 2026-09-10T12:17:00.000Z Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-next-gen-telomere-targeting-therapies BiopharmaWatch en 2026-09-10T12:15:00.000Z MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026 https://www.biopharmawatch.com/news/ONCY/oncolytics-pelareorep-ras-inhibitor-colorectal-cancer BiopharmaWatch en 2026-09-10T12:15:00.000Z Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer https://www.biopharmawatch.com/news/CADL/candel-therapeutics-appoints-martine-zimmermann BiopharmaWatch en 2026-09-10T12:05:00.000Z Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-dermatology-conferences-2026 BiopharmaWatch en 2026-09-10T12:05:00.000Z Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-stifel-2026-forum BiopharmaWatch en 2026-09-10T12:00:00.000Z Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-arpa-h-give-program-rna-medicines BiopharmaWatch en 2026-09-10T12:00:00.000Z Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines https://www.biopharmawatch.com/news/CMPS/fluence-compass-pathways-comp360-training BiopharmaWatch en 2026-09-10T12:00:00.000Z Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-setmelanotide-espe-2026 BiopharmaWatch en 2026-09-10T12:00:00.000Z Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting https://www.biopharmawatch.com/news/LPCN/lipocine-presentation-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T12:00:00.000Z Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/LEGN/legend-biotech-carvykti-update-ims-meeting BiopharmaWatch en 2026-09-10T12:00:00.000Z Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting https://www.biopharmawatch.com/news/HUMA/humacyte-presentation-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T12:00:00.000Z Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ERAS/erasca-multiple-presentations-eortc-nci-aacr-symposium BiopharmaWatch en 2026-09-10T12:00:00.000Z Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium https://www.biopharmawatch.com/news/INAB/in8bio-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-10T12:00:00.000Z IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T12:00:00.000Z Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ADAG/adagene-third-arc-bio-lead-candidate-selection BiopharmaWatch en 2026-09-10T12:00:00.000Z Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology https://www.biopharmawatch.com/news/SCYX/scynexis-appoints-sanjay-subramanian-cfo BiopharmaWatch en 2026-09-10T12:00:00.000Z SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T12:00:00.000Z Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ICCM/icecure-medical-regulatory-approval-prosense-china BiopharmaWatch en 2026-09-10T11:58:00.000Z IceCure Medical Receives Regulatory Approval to Market ProSense® in China https://www.biopharmawatch.com/news/ELAN/elanco-participate-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-09-10T11:58:00.000Z Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/RHEL/rhelion-life-sciences-ibex011-stability-program BiopharmaWatch en 2026-09-10T11:55:00.000Z Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-phase-1-2-trial-authorization BiopharmaWatch en 2026-09-10T11:33:00.000Z CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder https://www.biopharmawatch.com/news/HELP/helus-pharma-participate-morgan-stanley-conference BiopharmaWatch en 2026-09-10T11:30:29.000Z Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York https://www.biopharmawatch.com/news/AGEN/agenus-three-year-survival-data-igcs-2026 BiopharmaWatch en 2026-09-10T11:30:00.000Z Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 https://www.biopharmawatch.com/news/MDCX/medicus-pharma-publishes-abridged-final-phase-2-skinject-clinical-study BiopharmaWatch en 2026-09-10T11:30:00.000Z Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T11:30:00.000Z TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/IMRX/immuneering-aacr-conference-atebimetinib-pancreatic-cancer BiopharmaWatch en 2026-09-10T11:30:00.000Z Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival https://www.biopharmawatch.com/news/CRVO/cervomed-phase-2a-trial-neflamapimod-nfvppa-results BiopharmaWatch en 2026-09-10T11:30:00.000Z CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026 https://www.biopharmawatch.com/news/RVX/resverlogix-apabetalone-heart-failure-publication BiopharmaWatch en 2026-09-10T11:15:00.000Z Resverlogix Announces Publication of Scientific Journal Articles Relating to Apabetalone's Prevention of Heart Failure https://www.biopharmawatch.com/news/CNSY/cerenome-announces-financing-facility-royalty-repayment BiopharmaWatch en 2026-09-10T11:15:00.000Z Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-fda-clearance-prt13722 BiopharmaWatch en 2026-09-10T11:01:00.000Z Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader https://www.biopharmawatch.com/news/STAA/staaar-surgical-global-report-lens-correction BiopharmaWatch en 2026-09-10T11:00:00.000Z STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction https://www.biopharmawatch.com/news/ALKS/alkermes-launch-pathways-research-awards-2026 BiopharmaWatch en 2026-09-10T11:00:00.000Z Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-phase-3-data-psych-congress-2026 BiopharmaWatch en 2026-09-10T11:00:00.000Z Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 https://www.biopharmawatch.com/news/NKTX/nkarta-september-investor-conferences-2026 BiopharmaWatch en 2026-09-10T11:00:00.000Z Nkarta to Participate in September Investor Conferences https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-dreams-grant-recipients-2026 BiopharmaWatch en 2026-09-10T11:00:00.000Z Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program https://www.biopharmawatch.com/news/LH/labcorp-strategic-priorities-2026-investor-day BiopharmaWatch en 2026-09-10T11:00:00.000Z Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day https://www.biopharmawatch.com/news/CLGN/collplant-lightsolver-investor-webinar-september-2026 BiopharmaWatch en 2026-09-10T11:00:00.000Z CollPlant to Host LightSolver Investor Webinar on September 17, 2026 https://www.biopharmawatch.com/news/CTSO/cytosorbents-present-h-c-wainwright-28th-annual-global-investment-conference BiopharmaWatch en 2026-09-10T11:00:00.000Z CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-10T11:00:00.000Z Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/KMDA/kamada-presents-hc-wainwright-investment-conference BiopharmaWatch en 2026-09-10T11:00:00.000Z Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/CMPS/compass-pathways-grant-program-psychedelic-training BiopharmaWatch en 2026-09-10T10:35:00.000Z Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training https://www.biopharmawatch.com/news/CMPS/compass-pathways-investor-conferences-september-2023 BiopharmaWatch en 2026-09-10T10:30:00.000Z Compass Pathways to Participate in Investor Conferences the Week of September 14th https://www.biopharmawatch.com/news/AXGN/axogen-pricing-public-offering-common-stock BiopharmaWatch en 2026-09-10T10:01:00.000Z Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock https://www.biopharmawatch.com/news/AXGN/axogen-acquires-biocircuit-technologies BiopharmaWatch en 2026-09-10T10:00:00.000Z Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies https://www.biopharmawatch.com/news/KMTS/kestra-names-daniel-finney-vp-research-development BiopharmaWatch en 2026-09-10T10:00:00.000Z Kestra Names Daniel Finney Vice President of Research & Development https://www.biopharmawatch.com/news/JAGX/jaguar-health-crofelemer-mvid-trial-extension BiopharmaWatch en 2026-09-10T09:00:00.000Z All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF) https://www.biopharmawatch.com/news/CVS/updated-covid-19-vaccines-available-cvs-pharmacy-minuteclinic-across-u BiopharmaWatch en 2026-09-10T08:45:00.000Z Updated COVID-19 Vaccines Available at CVS Pharmacy and MinuteClinic Across the U.S. https://www.biopharmawatch.com/news/IPHA/innate-pharma-conference-call-september-2026 BiopharmaWatch en 2026-09-10T05:00:00.000Z Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/IRON/disc-medicine-restore-pv-phase-2-results BiopharmaWatch en 2026-09-09T23:25:00.000Z Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting https://www.biopharmawatch.com/news/NVRS/noveris-health-sciences-2026-meeting-results BiopharmaWatch en 2026-09-09T21:05:00.000Z Noveris Health Sciences Announces Results of 2026 Annual General and Special Meeting https://www.biopharmawatch.com/news/ACTU/actuate-present-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T21:00:00.000Z Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/INM/inmed-fiscal-2026-results-mentari-merger-update BiopharmaWatch en 2026-09-09T20:30:00.000Z InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-morgan-stanley-conference BiopharmaWatch en 2026-09-09T20:30:00.000Z Phibro Animal Health Corporation to Participate in Morgan Stanley Annual Global Healthcare Conference https://www.biopharmawatch.com/news/SI/shoulder-innovations-partnership-alm-ortho BiopharmaWatch en 2026-09-09T20:24:00.000Z Shoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures https://www.biopharmawatch.com/news/LEXX/lexaria-closes-warrant-exercise-5-9-million BiopharmaWatch en 2026-09-09T20:20:03.000Z Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds https://www.biopharmawatch.com/news/COO/coopercompanies-third-quarter-2026-results BiopharmaWatch en 2026-09-09T20:17:00.000Z CooperCompanies Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-q1-fiscal-2027-results BiopharmaWatch en 2026-09-09T20:15:00.000Z Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2027 https://www.biopharmawatch.com/news/BKD/brookdale-reports-august-2026-occupancy BiopharmaWatch en 2026-09-09T20:15:00.000Z Brookdale Reports August 2026 Occupancy https://www.biopharmawatch.com/news/NBTX/nanobiotix-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T20:15:00.000Z NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment https://www.biopharmawatch.com/news/NBTX/nanobiotix-hc-wainwright-investment-conference-2026 BiopharmaWatch en 2026-09-09T20:15:00.000Z NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-09T20:11:00.000Z Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/PRTA/prothena-hc-wainwright-investment-conference BiopharmaWatch en 2026-09-09T20:05:00.000Z Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ELMD/electromed-participate-hc-wainwright-ld-micro-conference BiopharmaWatch en 2026-09-09T20:05:00.000Z Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event https://www.biopharmawatch.com/news/MGNX/macrogenics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-09T20:05:00.000Z MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/IPSC/century-therapeutics-appoints-joseph-truitt-board BiopharmaWatch en 2026-09-09T20:05:00.000Z Century Therapeutics Appoints Joseph Truitt to Board of Directors https://www.biopharmawatch.com/news/ASND/ascendis-transcon-cnp-infant-data-espe-2026 BiopharmaWatch en 2026-09-09T20:01:00.000Z First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026 https://www.biopharmawatch.com/news/DGX/apple-health-app-quest-diagnostics-labs BiopharmaWatch en 2026-09-09T20:01:00.000Z Apple Health app Users to be Able to Order Labs from Quest Diagnostics https://www.biopharmawatch.com/news/AMGN/amgen-presents-morgan-stanley-global-healthcare-conference BiopharmaWatch en 2026-09-09T20:01:00.000Z AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-attend-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-09T20:01:00.000Z Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference https://www.biopharmawatch.com/news/GNLX/genelux-olvi-vec-small-cell-lung-cancer-response BiopharmaWatch en 2026-09-09T20:01:00.000Z Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy https://www.biopharmawatch.com/news/GH/guardant-health-2026-wclc-abstracts BiopharmaWatch en 2026-09-09T19:46:00.000Z Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer https://www.biopharmawatch.com/news/EFSI/investigation-eagle-financial-services-efsi BiopharmaWatch en 2026-09-09T19:21:00.000Z $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Eagle Financial Services, Inc. (NASDAQ: EFSI) https://www.biopharmawatch.com/news/CSR/investigation-centerspace-sale-irt BiopharmaWatch en 2026-09-09T19:18:00.000Z $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centerspace (NYSE: CSR) https://www.biopharmawatch.com/news/INV/class-action-lawsuit-innventure-investors BiopharmaWatch en 2026-09-09T18:43:00.000Z Berger Montague PC Investigating Claims on Behalf of Investors in Innventure, Inc. (NASDAQ: INV) After Class Action Filing https://www.biopharmawatch.com/news/MRVL/marvel-biosciences-private-placement-extension BiopharmaWatch en 2026-09-09T18:37:00.000Z Marvel Biosciences annonce la prolongation de la date limite de clôture du placement privé https://www.biopharmawatch.com/news/MRVL/marvel-biosciences-announces-extension-closing-date-private-placement BiopharmaWatch en 2026-09-09T18:32:00.000Z Marvel Biosciences Announces Extension to Closing Date of Private Placement